The clinical practice directives included for breast and ovarian cancer prevention largely rely on the same genetic tests, (BRCA1/2), STK11, TP53, and differed in aspects like the recommended target age, or specific intervention details. This evidence concerns the gene TP53 and ovarian carcinoma.